Explore more publications!

Massachusetts Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.

Press releases published on March 27, 2026

BAE Systems Honors GreenSource Fabrication with a Partner 2 Win Supplier of the Year Award
Powerful Book Reveals How Empathy Can Prevent Violence, Racism, and Political Corruption
ShantyTown, the Calming City-Builder, Now at PAX East 2026
Open Education Global, MIT Open Learning, and OLERAC to Co-Host Hybrid OEGlobal 2026 Conference in Cambridge, MA
Trilio Achieves Red Hat Premier Partner Status, Advancing Data Protection Across OpenShift & Red Hat’s Sovereign Cloud
GreenBanana SEO Named Best AI SEO Agency by Visualmodo
Crescent Biopharma Announces Grants of Inducement Awards
Cue Biopharma Announces CEO Transition
Cambridge Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing March 30, 2026
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
Beacon Hill Appoints Amy Hess as Director of Associates in Denver
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
AI Is Reshaping Neuroprotective Drug Discovery Market: New BCC Research Pulse Report Maps the Investment and Innovation Landscape
Vor Bio Announces $75 Million Private Placement with TCGX
Precision Optics Corporation, Inc. Announces Pricing of Upsized $10 Million Public Offering of Common Stock
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Global study shows energy industry ramping up investment in autonomous operations by 2030 as AI reshapes performance
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions